4-(3-Chloropropyl)morpholine CAS 7357-67-7 Gefitinib Intermediate Purity >98.0% (GC)
Ruifu Chemical is the leading manufacturer of 4-(3-Chloropropyl)morpholine (CAS: 7357-67-7) with high quality, intermediate of Gefitinib (CAS: 184475-35-2). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase 4-(3-Chloropropyl)morpholine, Please contact: alvin@ruifuchem.com
| Chemical Name | 4-(3-Chloropropyl)morpholine |
| Synonyms | N-(3-Chloropropyl)morpholine; 3-Morpholinopropyl Chloride; 1-Chloro-3-(Morpholin-4-yl)propane; 1-Chloro-3-Morpholinopropane; 3-(Morpholin-4-yl)propyl Chloride; 3-Chloro-1-(Morpholin-4-yl)propane; Gefitinib Impurity VI |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 7357-67-7 |
| Molecular Formula | C7H14ClNO |
| Molecular Weight | 163.65 g/mol |
| Boiling Point | 115℃/25mmHg(lit.) |
| Flash Point | 91℃ |
| Sensitive | Air Sensitive, Heat Sensitive |
| COA & MSDS | Available |
| Sample | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | Colorless to Light Yellow Clear Liquid | Complies |
| Purity / Analysis Method | >98.0% (GC) | 99.35% |
| Water by Karl Fischer | <0.50% | 0.26% |
| Maximurn Single Impurity | <0.50% | <0.50% |
| Total Impurities | <2.00% | 0.65% |
| Refractive Index n20/D | 1.4705~1.4765 | Complies |
| Density (20℃) | 1.077~1.081 | Complies |
| 1 H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Gefitinib (CAS: 184475-35-2) | |
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Risk Codes
36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
RTECS QE0488000
Hazard Class IRRITANT
4-(3-Chloropropyl)morpholine (CAS: 7357-67-7) is an intermediate of Gefitinib (CAS: 184475-35-2). Gefitinib, is a drug used for certain breast, lung , and other cancers, also known as Iressa, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the treatment of prior locally advanced or metastatic non-chemical treatment or unsuitable for chemotherapysmall cell lung cancer (NSCLC). Gefitinib is a highly specific anti-tumor targeted therapy drug developed by AstraZeneca in the United Kingdom. It is the first molecularly targeted drug for the treatment of non-small cell lung cancer.
